Eli Lilly (LLY) R&D In Process (2009 - 2026)

Eli Lilly has reported R&D In Process for 17 years, with the latest figure at $584.0 million in Q1 2026.

• For the quarter ending Q1 2026, R&D In Process fell 62.85% year-over-year to $584.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (down 59.46% YoY), and the FY2025 full-year result was $2.9 billion, down 11.28% from the prior year.
• R&D In Process for Q1 2026 stood at $584.0 million, up from $530.0 million in the prior quarter.
• The five-year high for R&D In Process was $3.0 billion in Q3 2023, with the low at $62.4 million in Q3 2022.
• Historically, R&D In Process has averaged $676.0 million across 5 years, with a median of $240.1 million in 2022.
• The largest YoY upside for R&D In Process was 4675.64% in 2023 against a maximum downside of 77.95% in 2023.
• Eli Lilly's R&D In Process stood at $240.1 million in 2022, then surged by 159.39% to $622.8 million in 2023, then plunged by 69.69% to $188.8 million in 2024, then surged by 180.72% to $530.0 million in 2025, then rose by 10.19% to $584.0 million in 2026.
• The last three R&D In Process figures came in at $584.0 million (Q1 2026), $530.0 million (Q4 2025), and $655.7 million (Q3 2025), per Business Quant data.